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Objective: To determine the medium-term outcome of Ahmed implants inserted through a 
needle tract at 5 mm from limbus that eliminates the need for a donor scleral graft.
Methods: A retrospective case series of 19 patients undergoing Ahmed implant surgery for 
refractory glaucoma with a mean follow-up of 12 months. Primary outcome measures included 
control of intraocular pressure after surgery. Secondary outcome measure included the frequency 
of intraoperative and postoperative complications.
Results: Intraocular pressure was maintained between 6 and 21 mmHg throughout the study. 
There was no postoperative hypotony. There were no complications related to this modified 
technique.
Conclusion: Needle tract at 5 mm from limbus maintains implant’s ability to control intraocular 
pressure and eliminates the need for a donor scleral graft or heterologous material.
Keywords: surgical technique, Ahmed implant, refractory glaucoma, donor scleral graft, tube 
shunt device
Introduction
Glaucoma drainage devices are helpful in the management of glaucomas that do not 
respond well to conventional medical and surgical therapy, in eyes with prior multiple 
surgeries, and in eyes with neovascular glaucomas. Shunts seem to have advantages 
over standard surgery in uveitis-related glaucomas. In summary, although the primary 
indication for aqueous shunts is when prior medical or surgical therapy has failed, 
they may be used as primary surgical therapy for selected conditions such as trauma, 
chemical burns, or pemphigoid (level III evidence).1 Based on level I evidence, aqueous 
shunts offer a valuable alternative to standard filtering surgery or to cyclodestructive 
therapy for many refractory glaucomas. The failure rate is approximately the same 
rate as for trabeculectomy with adjunctive antifibrotic agents, and in favorable cases, 
shunts may continue to function to control intraocular pressure (IOP) for more than 
two decades.2
Molteno first described the use of his implant in 1969.3 Other drainage devices are 
the Ahmed valve, Baerveldt device, and Krupin valve.4 These devices drain aqueous 
humor from the anterior chamber through a tube to a posterior plate. The aqueous 
humor crosses the pseudocyst around the plate by passive diffusion and is removed by 
venous capillaries or lymphatics. The Ahmed Glaucoma Valve (New World Medical, 
Inc., Rancho Cucamonga, CA) is a glaucoma drainage device that has a 184-mm2 plate 
and a unidirectional valve, which minimizes postoperative hypotony and complications 
associated with hypotony during the immediate postoperative period.Clinical Ophthalmology 2010:4 360
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Additional IOP reduction and long-term success after 
glaucoma drainage implant surgery may be related to the 
degree of encapsulation around the implant plate, which 
provides resistance to the aqueous flow.
The tube has a long extrascleral course that must be 
covered by donor material such as sclera, dura, or pericardium 
to prevent conjunctival erosion of the tube.5,6 Concerns 
have been raised regarding the potential risk of iatrogenic 
transmission of variant Creutzfeldt-Jakob disease (vCJD) 
via graft tissue.7
Ozdamar and colleagues described the results of a scleral 
tunnel without scleral graft in six patients with a Krupin 
valve implanted.8
In this study we describe the results using a needle tract 
at 5 mm from limbus for tube placement of silicone Ahmed 
implants in a series of 19 patients with a 12-month follow-up. 
This technique eliminates of the need for a donor scleral graft 
to cover the site of tube placement.
Methods
Patients for this study were recruited from Hospital Universitari 
Bellvitge (Barcelona, Spain). Nineteen consecutive patients 
were operated on over the period 2006 to 2008 using a modi-
fied technique consisting of a needle tract located at 5 mm 
from corneal limbus and were included in this study.
For inclusion, patients had elevated IOP that was not 
responsive to conventional medical and surgical therapy 
or had significant conjunctival scarring or inflammation 
precluding trabeculectomy. Exclusion criteria included 
patients younger than 18 years, eyes requiring combined 
surgery, or eyes with previous cyclodestructive treatment, 
silicone oil treatment, or previous glaucoma drainage device 
implantation. All patients were treated with a silicone (model 
FP7) Ahmed valve.
Information collected before surgery included gender, 
age, glaucoma diagnosis, lens status, history of laser and 
surgical treatments, IOP, visual acuity (VA), and glaucoma 
medications. At each follow-up visit (at weeks 1, 4, 6, 8, and 
at 12 months postoperatively) the following variables were 
analyzed: IOP, number of glaucoma medications, VA, and 
presence of complications.
Bellvitge Hospital human ethics committee approved 
the study and it was in adherence with the Declaration of 
Helsinki.
A fornix based conjunctival flap is the first step. 
A paracentesis with a 30G needle with the extraction of 
0.1 mL of aqueous humor and injection of an ophthalmic 
viscoelastic device (OVD) under the presumed place of entry 
of the tube is performed. A tract with a 23 gauge needle 
connected to an OVD is performed 5 mm posterior to the 
limbus. The needle should be visible within the sclera and 
penetrate the anterior chamber in a plane parallel to the iris 
to avoid trauma.
The 23G needle is then carefully removed injecting the 
OVD. The Ahmed tube is trimmed at the desired length 
and inserted into the anterior chamber through the tract 
created by the needle and the OVD is fixed using two pairs 
of forceps. The technique is even easier on pseudophakic 
patients as the tube can be placed in the posterior chamber 
between iris and intraocular lens. Finally the conjunctiva 
is closed.
An XLSTAT for Microsoft Excel (version 2009.4.01; 
Micro soft, Redmond, WA) program was used for statistical 
analysis. The paired Wilcoxon test was used to assess dif-
ferences in continuously scaled variables both before and 
after surgery.
VA measurements were converted to logMAR equivalents 
to perform analysis. A statistically significant difference was 
defined as a P-value 0.05, 95% confidence intervals (CI) 
were used to assess plausible ranges of true differences.
Only the first procedure of patients with bilateral Ahmed 
valve implantation was included in the analysis in order to 
avoid the effects of correlation.
Results
A total of 19 consecutive patients underwent Ahmed implant 
surgery with this modified method. Demographic data are 
shown in Table 1. The male to female ratio was 9:1 with 
a mean age of 69.5 years (range 38–89 years). The mean 
duration of follow up was 24.5 months. Ten cases were 
neovascular glaucoma (NVG). None of them received 
anti-vascular endothelial growth factor (VEGF) therapy.
IOP data obtained over the course of the study are 
summarized in Table 2. The mean preoperative IOP was 39 
(standard deviation [SD] 10.63) mmHg and fell to 10 (SD 
3.77) mmHg by the final postoperative visit. An average 
postoperative pressure reduction of 19 mmHg from baseline 
was observed (95% CI: 1.70 mmHg; P  0.01).
The mean number of glaucoma medications preopera-
tively was 3 (SD 0.7) dropping to 0 (SD 0.38) at the final 
postoperative visit (at 12 months).
VA improved in 36.84%, remained unchanged in 57.89%, 
and worsened in 5.26% of patients.
In the immediate postoperative period (1 month) 
complications included: four cases of hyphema; two cases 
of flat AC; and one case of hypotony. One of the cases with Clinical Ophthalmology 2010:4 361
Graft free Ahmed valve Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 1 Baseline characteristics
Case, age, sex, lens status Glaucoma diagnosis logMAR BCVA IOP-pre Number of  
medications
  1, 59, M, Phakic Neovascular 2 56 2
  2, 89, F, Pseudophakic POAG 1.6 27 3
  3, 53, M, Phakic Neovascular 3 42 2
  4, 73, M, Pseudophakic Neovascular 0.4 32 3
  5, 69, M, Pseudophakic Neovascular 0.8 40 2
  6, 69, M, Pseudophakic Uveitis 3 26 3
  7, 55, M, Phakic Traumatic 1 30 2
  8, 74, M, Phakic Neovascular 0.7 40 3
  9, 78, M, Phakic CCSF 0.7 45 1
10, 53, M, Phakic Neovascular 2 50 3
11, 72, M, Pseudophakic POAG 2 26 2
12, 70, M, Phakic Neovascular 2 54 3
13, 54, F, Phakic Neovascular 3 60 1
14, 69, M, Pseudophakic Neovascular 3 45 3
15, 38, M, Phakic Neovascular 2 38 3
16, 38, M Phakic Neovascular 2 36 3
17, 73, M, Phakic Neovascular 0.4 30 2
18, 52, M, Phakic POAG 0.7 41 3
19, 72, M, Phakic POAG 0.7 31 3
  Median: 69.5
SD: 13.46
CI: 6.05
Median: 2  
SD: 0.9388  
CI: 0.42
Median: 39  
SD: 10.63  
CI: 4.77
Abbreviations: M, male; F, female; BCVA, best-corrected visual acuity; CCSF, carotid-cavernous sinus fistula; POAG, primary open-angle glaucoma; SD, standard deviation; CI, 
confidence intervals.
Table 2 Intraocular pressure over the study
Case Intraocular pressure Number of medications  
(postoperative)
Month 1 Month 3 Month 6 Month 9 Month 12
1 12 14 12 14 14 0
2 18 16 18 16 14 1
3 11 10 10 10 10 0
4 11 12 12 12 12 0
5 11 10 10 10 10 0
6 12 14 10 10 12 0
7 8 10 14 16 10 0
8 12 14 14 10 10 1
9 26 18 20 26 20 1
10 6 8 18 8 6 0
11 12 14 6 10 12 0
12 8 8 8 6 8 0
13 15 14 14 14 18 0
14 10 12 12 10 10 0
15 16 16 14 16 16 0
16 16 14 14 14 12 0
17 6 6 6 6 6 0
18 8 6 8 10 8 0
19 8 8 6 6 8 0
Median: 11  
SD: 4.80  
CI: 2.17
Median: 12  
SD: 3.52  
CI: 1.58
Median: 12  
SD: 3.85  
CI: 1.73
Median: 10  
SD: 4.75  
CI: 2.13
Median: 10  
SD: 3.77  
CI: 1.70
Abbreviations: SD, standard deviation; CI, confidence intervals.Clinical Ophthalmology 2010:4 362
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hyphema showed the tube was blocked with fibrin needing no 
hypotensive treatment as IOP was maintained under 8 mmHg 
(due to a little choroidal detachment). Other complications are 
listed in Table 3. There was a case of corneal decompensation 
due to a pseudophakic bullous keratopathy not related to 
corneal-tube touch, as the tube was implanted behind the 
iris. No cases of corneal-tube touch were noted. There was 
no erosion of the conjunctiva overlying the tube portion 
of the Ahmed implants or tube migration in any patient in 
the study.
Discussion
There are several complications of aqueous shunts, including 
erosion of the tube or explant through overlying conjunctiva 
that require explanation. The most problematic long-term 
consequence of anterior chamber tube placement is acceler-
ated damage to the corneal endothelium over time. Due to the 
fear that conjunctival erosion leading to tube exposure and 
endophthalmitis may occur,9 donor scleral grafts have been 
used by most surgeons.6,10 Erosion of the tube may occur over 
a period of weeks to months. If the tube is exposed, difficult 
and extensive lateral dissection is often necessary to achieve 
sufficient conjunctival mobility to recover a repatched tube. 
Conjunctival grafts, placement of amniotic membrane, or 
both may be necessary.7,11 The modified technique described 
in this study successfully eliminates the need for a donor 
scleral graft or heterologous material.
Ozdamar and colleagues described the use of a 10 mm 
scleral tunnel for the insertion of a Krupin eye valve.8 They 
reported complete or qualified success in the six patients of 
the study over a 7-month follow up. No conjunctival erosion 
or tube displacement was observed. They proposed that this 
scleral tunnel placed at 10 mm from corneal limbus would 
prevent migration by improving the stability of the tube; 
however, our experience suggests, for Ahmed implants, a 
5 mm needle tract may be sufficient, as erosion occurs most 
frequently about 2 mm from the limbus.12
Similar to other studies, complete success was defined as 
an IOP between 6 mmHg and 21 mmHg, without additional 
hypotensive medications and qualified success as an IOP 
between 6 mmHg and 21 mmHg with additional medication. 
Failure was defined as an IOP  21 mmHg, hypotony 
(IOP  6 mmHg), a requirement for cyclodestructive 
procedure, or further glaucoma surgery. Our analysis showed 
a significant reduction in the mean IOP following surgery 
associated with a decrease in the number of glaucoma 
medications required.
Complications in this series are similar to previous 
reports, corneal decompensation being the most common 
event (20.6%).4,13–15 Lim and colleagues suggest this may 
result from suboptimal tissue compatibility and possibly 
micromotion from the tube element.4 Cornea-tube touch is 
another cause of corneal decompensation.14
This modified surgical technique eliminates the need for 
covering the tract with homologous or heterologous material. 
A shorter operative time may be anticipated by the surgeon. 
There were no complications directly attributable to the 
lack of covering of the tube by homologous or heterologous 
material. Nevertheless, we cannot establish superiority of 
this modified technique in the absence of a control group 
using a scleral patch.
There were no cases of conjunctival erosion in this series 
of patients over the follow-up period. This outcome may 
be related to an absence of the immune mediated processes 
leading to thinning of grafts.5,13,15–19
This study has limitations that may have influenced the 
results: one being the relatively short follow-up period. 
Erosion through the typical scleral graft occurs most 
  frequently about 2 mm form the limbus and can occur from 
months to years after installation, therefore necessitating 
long follow-up periods before comparisons to “standard” 
techniques. Another limitation of this study is the relatively 
small sample size.
This study describes a simplified alternative surgical 
technique for the insertion of implants which provides IOP 
control in the first postoperative year and eliminates the 
requirement for homologous or heterologous material. There 
were no postoperative complications associated specifically 
to this method.
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